OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

The company believes that better and earlier detection of cancer through liquid biopsies will:


  • Improve patient outcomes
  • Increase the life expectancy of cancer patients
  • Significantly reduce health care costs

Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.

These invasive tests are expensive, time-consuming when time may be of utmost importance, and lead to both patient anxiety and physician uncertainty about the diagnosis.

Our next generation liquid biopsy diagnostics will use blood or urine samples to detect the presence or absence of cancer. These diagnostics are:

  • Simple
  • Accurate
  • Fast
  • Non-invasive

OncoCyte’s initial focus is on cancers with large patient populations and significant unmet need.

Show more
Type
Public
HQ
Alameda, US
Size (employees)
15 (est)
OncoCyte Corporation is headquartered in Alameda, US
Report incorrect company information

Key People/Management at OncoCyte Corporation

William Annett

William Annett

President & Chief Executive Officer
Lyssa Friedman

Lyssa Friedman

Vice President, Clinical and Regulatory Affairs
Lyndal Hesterberg

Lyndal Hesterberg

Senior Vice President, Research & Development
Mitch Levine

Mitch Levine

CFO
Kristine C. Mechem

Kristine C. Mechem

Vice President, Marketing & Planning
William Seltzer

William Seltzer

Vice President, Clinical Services
Show more

OncoCyte Corporation Office Locations

OncoCyte Corporation has an office in Alameda
Alameda, US (HQ)
102 1010 Atlantic Ave
Show all (1)
Report incorrect company information

OncoCyte Corporation Financials and Metrics

OncoCyte Corporation Revenue

USD

Net income (Q1, 2018)

(3.8 m)

EBIT (Q1, 2018)

(3.9 m)

Market capitalization (11-Jul-2018)

124.1 m

Closing share price (11-Jul-2018)

3.2

Cash (31-Mar-2018)

12.6 m
OncoCyte Corporation's current market capitalization is $124.1 m.
Annual
USDFY, 2016

General and administrative expense

5.5 m

R&D expense

5.7 m

Operating expense total

11.1 m

EBIT

(11.1 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Sales and marketing expense

655 k477 k710 k658 k

General and administrative expense

1.2 m1.3 m1.2 m2 m1.1 m4.3 m1.8 m

R&D expense

1.7 m1.2 m1.4 m1.8 m2 m1.8 m1.5 m

Operating expense total

2.9 m(2.5 m)(2.6 m)4.5 m(3.6 m)(6.8 m)3.9 m
Annual
USDFY, 2016

Cash

10.2 m

Accounts Receivable

14.3 m

Inventories

285 k

Current Assets

12.7 m
Quarterly
USDQ3, 2017Q1, 2018

Cash

11 m12.6 m

Inventories

457 k

Current Assets

12.5 m14.1 m

Total Assets

14.2 m15.6 m
Annual
USDFY, 2016

Net Income

(11.2 m)

Depreciation and Amortization

145 k

Inventories

101 k

Cash From Operating Activities

(7.5 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.9 m)(2.5 m)(2.6 m)(4.7 m)

Accounts Payable

403 k192 k870 k211 k
USDY, 2018

Financial Leverage

1.7 x
Show all financial metrics

OncoCyte Corporation Operating Metrics

FY, 2016

Patents Issued

1

Patents and Patent Applications

13
Show all operating metrics
Report incorrect company information

OncoCyte Corporation Online and Social Media Presence

Embed Graph
Report incorrect company information

OncoCyte Corporation Company Life and Culture

Report incorrect company information